Literature DB >> 16617349

The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis.

Marie-Julie Dubois1, Sébastien Bergeron, Hyo-Jeong Kim, Luce Dombrowski, Mylène Perreault, Bénédicte Fournès, Robert Faure, Martin Olivier, Nicole Beauchemin, Gerald I Shulman, Katherine A Siminovitch, Jason K Kim, André Marette.   

Abstract

The protein tyrosine phosphatase SHP-1 is a well-known inhibitor of activation-promoting signaling cascades in hematopoietic cells but its potential role in insulin target tissues is unknown. Here we show that Ptpn6(me-v/me-v) (also known as viable motheaten) mice bearing a functionally deficient SHP-1 protein are markedly glucose tolerant and insulin sensitive as compared to wild-type littermates, as a result of enhanced insulin receptor signaling to IRS-PI3K-Akt in liver and muscle. Downregulation of SHP-1 activity in liver of normal mice by adenoviral expression of a catalytically inert mutant of SHP-1, or after small hairpin RNA-mediated SHP-1 silencing, further confirmed this phenotype. Tyrosine phosphorylation of CEACAM1, a modulator of hepatic insulin clearance, and clearance of serum [125I]-insulin were markedly increased in SHP-1-deficient mice or SHP-1-deficient hepatic cells in vitro. These findings show a novel role for SHP-1 in the regulation of glucose homeostasis through modulation of insulin signaling in liver and muscle as well as hepatic insulin clearance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16617349     DOI: 10.1038/nm1397

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  52 in total

1.  T cell protein tyrosine phosphatase (TCPTP) deficiency in muscle does not alter insulin signalling and glucose homeostasis in mice.

Authors:  K Loh; T L Merry; S Galic; B J Wu; M J Watt; S Zhang; Z-Y Zhang; B G Neel; T Tiganis
Journal:  Diabetologia       Date:  2011-11-29       Impact factor: 10.122

2.  Altered BCR signalling quality predisposes to autoimmune disease and a pre-diabetic state.

Authors:  Sebastian Königsberger; Jan Prodöhl; David Stegner; Vanessa Weis; Martin Andreas; Martin Stehling; Theresa Schumacher; Ruben Böhmer; Ina Thielmann; Judith M M van Eeuwijk; Bernhard Nieswandt; Friedemann Kiefer
Journal:  EMBO J       Date:  2012-06-22       Impact factor: 11.598

3.  New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts.

Authors:  Donghui Li; James L Abbruzzese
Journal:  Clin Cancer Res       Date:  2010-07-20       Impact factor: 12.531

Review 4.  Hepatic Insulin Clearance: Mechanism and Physiology.

Authors:  Sonia M Najjar; Germán Perdomo
Journal:  Physiology (Bethesda)       Date:  2019-05-01

Review 5.  The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.

Authors:  Z Z Chong; K Maiese
Journal:  Histol Histopathol       Date:  2007-11       Impact factor: 2.303

6.  Eye vessels saved by rescuing their pericyte partners.

Authors:  David Antonetti
Journal:  Nat Med       Date:  2009-11       Impact factor: 53.440

7.  Hepatocyte glutathione peroxidase-1 deficiency improves hepatic glucose metabolism and decreases steatohepatitis in mice.

Authors:  Troy L Merry; Melanie Tran; Garron T Dodd; Salvatore P Mangiafico; Florian Wiede; Supreet Kaur; Catriona L McLean; Sofianos Andrikopoulos; Tony Tiganis
Journal:  Diabetologia       Date:  2016-09-15       Impact factor: 10.122

8.  Role of tyrosine phosphatase SHP-1 in the mechanism of endorepellin angiostatic activity.

Authors:  Alexander Nyström; Zabeena P Shaik; Donald Gullberg; Thomas Krieg; Beate Eckes; Roy Zent; Ambra Pozzi; Renato V Iozzo
Journal:  Blood       Date:  2009-09-29       Impact factor: 22.113

9.  Inflammation and insulin resistance: an old story with new ideas.

Authors:  Jason K Kim
Journal:  Korean Diabetes J       Date:  2010-06-30

10.  Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy.

Authors:  Pedro Geraldes; Junko Hiraoka-Yamamoto; Motonobu Matsumoto; Allen Clermont; Michael Leitges; Andre Marette; Lloyd P Aiello; Timothy S Kern; George L King
Journal:  Nat Med       Date:  2009-11-01       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.